Pathogenesis, Management and Prevention of Atypical Femoral Fractures

키워드

참고문헌 (39)

1. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 25, pp.2267~2294 (2010)
2. Odvina CV, "Severely suppressed bone turnover : a potential complication of alendronate therapy", J Clin Endocrinol Metab, 90, pp.1294~1301 (2005)
3. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 29, pp.1~23 (2014)
4. Schilcher J, "Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls", Bone, 52, pp.389~392 (2013)
5. Feldstein AC, "Incidence and demography of femur fractures with and without atypical features", J Bone Miner Res, 27, pp.977~986 (2012)
6. Allen MR, "Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra", Osteoporos Int, 19, pp.329~337 (2008)
7. Wang X, "Age-related changes in the collagen network and toughness of bone", Bone, 31, pp.1~7 (2002)
8. Zioupos P, "The role of collagen in the declining mechanical properties of aging human cortical bone", J Biomed Mater Res, 45, pp.108~116 (1999)
9. Tang SY, "Effects of non-enzymatic glycation on cancellous bone fragility", Bone, 40, pp.1144~1151 (2007)
10. Tang SY, "Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate", Osteoporos Int, 20, pp.887~894 (2009)
11. Vashishth D, "Influence of nonenzymatic glycation on biomechanical properties of cortical bone", Bone, 28, pp.195~201 (2001)
12. Viguet-Carrin S, "Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae", Bone, 39, pp.1073~1079 (2006)
13. Allen MR, "Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment", J Bone Miner Res, 22, pp.1759~1765 (2007)
14. Durchschlag E, "Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate", J Bone Miner Res, 21, pp.1581~1590 (2006)
15. Boskey AL, "Spectroscopic markers of bone quality in alendronate-treated postmenopausal women", Osteoporos Int, 20, pp.793~800 (2009)
16. Donnelly E, "Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures", J Bone Miner Res, 27, pp.672~678 (2012)
17. Allen MR, "Human femoral neck has less cellular periosteum, and more mineralized periosteum, than femoral diaphyseal bone", Bone, 36, pp.311~316 (2005)
18. Fournier P, "Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats", Cancer Res, 62, pp.6538~6544 (2002)
19. Wood J, "Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid", J Pharmacol Exp Ther, 302, pp.1055~1061 (2002)
20. Deckers MM, "Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice", J Bone Miner Res, 17, pp.998~1007 (2002)
21. Allen MR, "Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate", Bone, 39, pp.872~879 (2006)
22. Allen MR, "Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment", Calcif Tissue Int, 82, pp.354~360 (2008)
23. Mashiba T, "Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles", Bone, 28, pp.524~531 (2001)
24. Cao Y, "Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats", J Bone Miner Res, 17, pp.2237~2246 (2002)
25. Martinez MD, "Healing of non-displaced fractures produced by fatigue loading of the mouse ulna", Bone, 46, pp.1604~1612 (2010)
26. Barrett JG, "Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats", J Orthop Res, 25, pp.1070~1077 (2007)
27. Mori S, "Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures", Bone, 21, pp.521~526 (1997)
28. Schaffler MB, "Aging and matrix microdamage accumulation in human compact bone", Bone, 17, pp.521~525 (1995)
29. Allen MR, "Raloxifene enhances vertebral mechanical properties independent of bone density", Bone, 39, pp.1130~1135 (2006)
30. Stepan JJ, "Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis", Bone, 41, pp.378~385 (2007)
31. Chapurlat RD, "Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates : a bone biopsy study", J Bone Miner Res, 22, pp.1502~1509 (2007)
32. Crossley K, "Ground reaction forces, bone characteristics, and tibial stress fracture in male runners", Med Sci Sports Exerc, 31, pp.1088~1093 (1999)
33. Sasaki S, "Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur : a case series", J Bone Miner Metab, 30, pp.561~567 (2012)
34. Cohen A, "Discontinuing antiresorptive therapy one year after cardiac transplantation : effect on bone density and bone turnover", Transplantation, 81, pp.686~691 (2006)
35. Hershman DL, "Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment", J Clin Endocrinol Metab, 95, pp.559~566 (2010)
36. Black DM, "Effects of continuing or stopping alendronate after 5 years of treatment : the Fracture Intervention Trial Long-term Extension(FLEX) : a randomized trial", JAMA, 296, pp.2927~2938 (2006)
37. Mellström DD, "Seven years of treatment with risedronate in women with postmenopausal osteoporosis", Calcif Tissue Int, 75, pp.462~468 (2004)
38. Sorensen OH, "Long-term efficacy of risedronate : a 5-year placebo-controlled clinical experience", Bone, 32, pp.120~126 (2003)
39. Schwartz AV, "Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture : the FLEX trial", J Bone Miner Res, 25, pp.976~982 (2010)

관련 논문AI추천